The Psychedelic Syndicate: Part 4


Part 4 of The Psychedelic Syndicate reveals PSFC’s strategy to manufacture spiritual and moral authority through academic capture — even as some members align with far-right ideologies that deepen the very crises psychedelics are meant to heal.

The Psychedelic Syndicate: Executive Summary

A year-long investigation reveals how a small group of Silicon Valley elites sought to capture the psychedelic therapy industry — using a network of affiliated organizations to scapegoat critics while pressuring regulators to approve their botched MDMA clinical trials.

The Psychedelic Syndicate: Part 1

Part 1 of The Psychedelic Syndicate reveals how the Psychedelic Science Funders Collaborative (PSFC) — a wealthy network of Silicon Valley elites and Burning Man devotees — systematically captured the psychedelic movement by influencing MAPS, funding its subsidiary Lykos’ MDMA clinical trials, and promoting underground therapy through state legalization initiatives.

The Psychedelic Syndicate: Part 2

Part 2 of The Psychedelic Syndicate exposes the compromised foundation of PSFC's influence network — from the abuse scandals that undermined their preferred therapy model, to undisclosed ties with the sole FDA advisory committee member who voted unequivocally for MDMA approval. 

The Psychedelic Syndicate: Part 3

Part 3 of The Psychedelic Syndicate exposes how Silicon Valley's "move fast and break things" mentality infected psychedelic therapy, creating a culture where leaders rationalized patient harm as unavoidable for progress and ultimately embraced Trump administration officials who promised regulatory shortcuts.

The Psychedelic Syndicate: Part 4

Part 4 of The Psychedelic Syndicate reveals PSFC’s strategy to manufacture spiritual and moral authority through academic capture — even as some members align with far-right ideologies that deepen the very crises psychedelics are meant to heal.

The Psychedelic Syndicate: Selected Primary Source Documents

This appendix makes available numerous previously unreleased primary source documents to serve as resources for other researchers and reporters.



Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.

Support on Patreon
Make a one-time donation

Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.

A year-long investigation reveals how a small group of Silicon Valley elites sought to capture the psychedelic therapy industry — using a network of affiliated organizations to scapegoat critics while pressuring regulators to approve their botched MDMA clinical trials.

The Psychedelic Syndicate: Selected Primary Source Documents

This appendix makes available numerous previously unreleased primary source documents to serve as resources for other researchers and reporters.

Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.

Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.

Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.

Power Tripping offers an inside look at Psymposia and New York Magazine’s podcast “Cover Story: Power Trip.” Join the co-creators and the rest of the Psymposia team for deep dives into the histories, characters, and events that shaped our investigation.

Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.

Listen on Spotify, Apple Podcasts, or wherever podcasts are available.

Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.


Featured Stories

Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia

Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.


Featured Stories

Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia

Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.


Correcting the Record: What The New York Times Got Wrong

In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.


Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference

Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.


Church of Psilomethoxin, Part 1: Sacramental Skepticism. Is the Church in Denial?

This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.



Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.

Support on Patreon
Make a one-time donation

Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.


Featured Stories

Correcting the Record: What The New York Times Got Wrong


In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.

Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia


Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.

Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference


Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.

#48 – Drugs and Anti-Capitalism with Hilary Agro

We talk drugs and anti-capitalism with anthropology PhD candidate, Hilary Agro. Ranging from prohibition to psychedelic clinical trials and beyond, we explore the overlaps and differences in our analyses of the current psychedelic (and broader drug policy) landscape.


#47 – Part Two: Right Wing Psychedelia

We continue our discussion about Brian Pace and Neşe Devenot's recently published paper: "Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency" 


#46 – Part One: Right Wing Psychedelia

We discuss Brian Pace and Neşe Devenot's recently published paper: "Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency" 


#45 – Part Two: Digital Capitalism on Psychedelics with Emma Stamm

In part two of our conversation with Villanova visiting professor of philosophy Emma Stamm, we discuss the "psychedelic industry's" increasing fixation on digital capitalism. Looking at apps like MyDelica and hardware like Kernel's brain-scanning helmet, we discuss how the social implications of this technology extend well beyond psychedelia.


Join Our Newsletter

Independent reporting. Critical analysis. In your inbox.

Join Our Newsletter

Independent reporting. Critical analysis. In your inbox.

#49 – Part One: Jordan Peterson’s Psychedelic Hierarchy, ft. Thought Slime


In part 1 of this deep dive, Psymposia and Thought Slime analyze Jordan Peterson's fascination with psychedelics as an example of the reactionary, right-wing ideologies that have been developing within psychedelia in recent decades. Reacting to a 2021 podcast of Peterson's, we discuss the significance of Peterson's popularity among some prominent psychedelic researchers.

#52 – Right-Wing Psychedelia at University of Madison-Wisconsin


This presentation highlights the numerous contemporary and historical cases where the use of psychedelics failed to reduce authoritarian tendencies in users, or even facilitated adoption of authoritarian views.

#48 – Drugs and Anti-Capitalism with Hilary Agro


We talk drugs and anti-capitalism with anthropology PhD candidate, Hilary Agro. Ranging from prohibition to psychedelic clinical trials and beyond, we explore the overlaps and differences in our analyses of the current psychedelic (and broader drug policy) landscape.


Series

A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.


From Mining to Mushrooms

A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.


Corporadelic

A series on the intersection of psychedelics and capitalism, and the early investors making it happen.


Corporadelic

A series on the intersection of psychedelics and capitalism, and the early investors making it happen.

Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We reject corporate advertising and rely on contributions from our readers and listeners. Click here to donate today.

Privacy. Terms of Use. © Psymposia, Inc. All Rights Reserved

Psymposia is a 501(c)(3) research non-profit with a mission to educate the public on psychedelic science and harm reduction.

Privacy Terms of Use

shiftnav-1